Literature DB >> 21691334

Peripheral neuropathies: clinical prognostic scales in Guillain-Barré syndrome.

Nortina Shahrizaila, Nobuhiro Yuki.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21691334     DOI： 10.1038/nrneurol.2011.93

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

Authors:  R D Hadden; H Karch; H P Hartung; J Zielasek; B Weissbrich; J Schubert; A Weishaupt; D R Cornblath; A V Swan; R A Hughes; K V Toyka
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Axonal Guillain-Barré syndrome is underestimated in Europe?

Authors:  S Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-18       Impact factor: 10.154

3.  Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.

Authors:  B C Jacobs; P A van Doorn; P I Schmitz; A P Tio-Gillen; P Herbrink; L H Visser; H Hooijkass; F G van der Meché
Journal:  Ann Neurol       Date:  1996-08       Impact factor: 10.422

4.  Early recognition of poor prognosis in Guillain-Barre syndrome.

Authors:  C Walgaard; H F Lingsma; L Ruts; P A van Doorn; E W Steyerberg; B C Jacobs
Journal:  Neurology       Date:  2011-03-15       Impact factor: 9.910

Review 5.  Immunotherapy for Guillain-Barré syndrome: a systematic review.

Authors:  Richard A C Hughes; Anthony V Swan; Jean-Claude Raphaël; Djillali Annane; Rinske van Koningsveld; Pieter A van Doorn
Journal:  Brain       Date:  2007-03-02       Impact factor: 13.501

6.  Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.

Authors:  Krista Kuitwaard; Jenny de Gelder; Anne P Tio-Gillen; Wim C J Hop; Teun van Gelder; Albert W van Toorenenbergen; Pieter A van Doorn; Bart C Jacobs
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

7.  Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody.

Authors:  S Kuwabara; M Asahina; M Koga; M Mori; N Yuki; T Hattori
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

8.  Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome.

Authors:  Bart C Jacobs; Michiaki Koga; Wouter van Rijs; Karin Geleijns; Pieter A van Doorn; Hugh J Willison; Nobuhiro Yuki
Journal:  J Neuroimmunol       Date:  2008-02-21       Impact factor: 3.478

9.  A clinical prognostic scoring system for Guillain-Barré syndrome.

Authors:  Rinske van Koningsveld; Ewout W Steyerberg; Richard A C Hughes; Anthony V Swan; Pieter A van Doorn; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

10.  Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.

Authors:  L H Visser; F G van der Meché; J Meulstee; P P Rothbarth; B C Jacobs; P I Schmitz; P A van Doorn
Journal:  Neurology       Date:  1996-09       Impact factor: 9.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.